Ischemic stroke is a leading cause of death and disability in the Western world. At present, intravenous administration of tissue plasminogen activator within 3 h of symptom onset is the only proven ...

Please provide your email address to receive an email when new articles are posted on . Researchers engaged in a secondary analysis of the ESCAPE clinical trial in patients with acute ischemic stroke.

The registry data suggest improved outcomes without safety concerns, but confirmatory RCTs are needed, a researcher says.

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

BASEL, Switzerland—Multiple randomized trials presented last week at the European Stroke Organisation Conference (ESOC) 2024 have bolstered the case that tenecteplase (TNK) is an effective—if not ...

May 28, 2009 — A new science advisory from the American Heart Association (AHA)/American Stroke Association (ASA) has given the green light to the use of tissue plasminogen activator (tPA) to treat ...

Lumosa Therapeutics (Lumosa; 6535.TWO) and CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines ...

Stroke is the leading cause of long-term disability and preventable disability in the United States. It is also the fifth leading cause of death, killing nearly 130,000 people in the U.S. each year.

Adding oral anticoagulants (OACs) to standard antiplatelet therapy did not reduce recurrence in patients with acute ischaemic stroke (AIS) and no indication for oral anticoagulation; however, this ...

New research has found that music therapy sessions have a positive effect on the neurorehabilitation of acute stroke patients, as well as their mood. New research has found that music therapy sessions ...